Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Assets: 2019-2025

Historic Assets for Kymera Therapeutics (KYMR) over the last 5 years, with Sep 2025 value amounting to $1.1 billion.

  • Kymera Therapeutics' Assets rose 6.49% to $1.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year increase of 6.49%. This contributed to the annual value of $978.0 million for FY2024, which is 69.87% up from last year.
  • Per Kymera Therapeutics' latest filing, its Assets stood at $1.1 billion for Q3 2025, which was down 2.57% from $1.1 billion recorded in Q2 2025.
  • Over the past 5 years, Kymera Therapeutics' Assets peaked at $1.1 billion during Q2 2025, and registered a low of $434.4 million during Q2 2021.
  • For the 3-year period, Kymera Therapeutics' Assets averaged around $834.8 million, with its median value being $868.3 million (2024).
  • As far as peak fluctuations go, Kymera Therapeutics' Assets dropped by 13.48% in 2023, and later surged by 87.34% in 2024.
  • Over the past 5 years, Kymera Therapeutics' Assets (Quarterly) stood at $605.9 million in 2021, then decreased by 0.46% to $603.1 million in 2022, then declined by 4.54% to $575.8 million in 2023, then spiked by 69.87% to $978.0 million in 2024, then grew by 6.49% to $1.1 billion in 2025.
  • Its Assets stands at $1.1 billion for Q3 2025, versus $1.1 billion for Q2 2025 and $918.3 million for Q1 2025.